BioMarin Pharmaceutical (BMRN)

38.04 +0.28  +0.74%  Feb 09, 9:58PM Go Pro
Watch
View Full Chart BMRN Price Chart

Key Stats

Market Cap 4.25B
Revenue Growth 16.04%
Profit Margin -15.56%
Earnings Yield -0.53%
Dividend Yield 0.00%
Earnings Per Share TTM -0.20
PE Ratio
Price / Sales Ratio 9.78
52 Week High 38.66
52 Week Low 23.09
Beta 1.20
View Pro Ratings Details

YCharts Pro Ratings

Go Pro.
Learn More
  • Pro Value Score Go Pro
  • Pro Fundamental Score Go Pro
  • Pro Valuation from Historical Multiples Go Pro

Profile

Exchange: NASDAQGM       Sector: Healthcare       Industry: Biotechnology

BioMarin Pharmaceutical Inc. is a biotechnology firm based in Novato, California. It has offices and facilities in the US, South America, Asia and Europe. BioMarin's core business and research is in enzyme replacement therapies. BioMarin is the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin is also the first company to provide therapeutics for Phenylketonuria. The company sells its products to specialty pharmacies, hospitals acting as retailers, pharmaceutical wholesalers, and distributors in the United States, Europe, Latin America, and rest of the world. It has a collaboration agreement with Genzyme Corporation for the development of Aldurazyme; and an agreement with Merck Serono for the further development and commercialization of Kuvan and other products containing 6R-BH4 and PEG-PAL for PKU. BioMarin Pharmaceutical Inc. was founded in 1996.

1 Year Total Return Performance

This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). BioMarin Pharmaceutical is up N/A over the last year vs S&P 500 Total Return up N/A, Sanofi up N/A, and Seattle Genetics up N/A.

  • BMRN Total Returns
  • ^SPXTR Total Returns
  • SNY Total Returns
  • SGEN Total Returns

Fundamentals

Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.

Income Statement View Statement

Balance Sheet View Statement

Get Quote for

Pro Strategies Featuring BMRN

Did BioMarin Pharmaceutical make it into our Pro Portfolio Strategies?

Start your YCharts Pro membership now to find out.

BMRN Charts

Recent Quotes

Symbol Price Chg Chg % Market Cap
BMRN 38.04 0.28 0.74% 4.22B
AEIS 10.72 0.04 0.37% 473.87M
CTAS 38.04 -0.01 -0.03% 4.94B
KALU 50.74 -0.48 -0.94% 988.03M
SIVB 57.99 -1.10 -1.87% 2.55B
ADPT 26.00 -0.25 -0.95%
MOLX 27.69 0.33 1.21% 4.81B
CASH 18.70 0.20 1.08% 57.72M
ADES 21.49 0.15 0.70% 163.46M
SPEX 1.05 -0.01 -0.94% 2.71M
You must be signed in to use watchlists.
Sign In or Register
Create Watchlist from Stock Quotes
Close